New Model IDs Inflammatory Asthma Without Sputum

Share this content:
New Model IDs Inflammatory Asthma Without Sputum
New Model IDs Inflammatory Asthma Without Sputum

WEDNESDAY, Jan. 4, 2017 (HealthDay News) -- A new prediction model identifies eosinophilic asthma without the need for sputum induction, according to a study published online Dec. 28 in Allergy.

Bart Hilvering, M.D., from University Medical Centre Utrecht in the Netherlands, and colleagues compared the activation state of eosinophils and neutrophils in peripheral blood to sputum analysis to assess asthma phenotype and monitor disease. The training cohort included 115 adult asthma patients, while the validation cohort included 34 patients.

The researchers found that a combination of data from multiple sources (blood eosinophil count, fractional exhaled nitric oxide, an asthma control questionnaire, medication use, nasal polyposis, aspirin sensitivity, and neutrophil/eosinophil responsiveness upon stimulation with formyl-methionyl-leucyl phenylalanine) identified sputum eosinophilia with 90.5 percent sensitivity and 91.5 percent specificity in the training cohort. Sensitivity and specificity were 77 and 71 percent, respectively, in the validation cohort, which had a relatively high percentage of patients on oral corticosteroids.

"The proposed prediction model identifies eosinophilic asthma without the need for sputum induction," the authors write. "The model forms a non-invasive and externally validated test to assess eosinophilic asthma in patients not on oral corticosteroids."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »